Follow the Faeth Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €892m. The latest transaction was filed on 11 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: STEPHENSON BRIAN C. The full history is accessible without an account.
20
Insider Decl.
n/a
Thresholds
n/a
17 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Faeth Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$54.64.
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Faeth Therapeutics, Inc. es una empresa centrada en el desarrollo de terapias innovadoras para enfermedades metabólicas. Cotiza en NASDAQ bajo el ticker XNAS.